Bination antiretroviral therapy (cART). In: 14th European AIDS Conference (EACS 2013). Brussels

12. Kolber MA, Gabr AH, De La Rosa A, Glock JA, Jayaweera D, Miller N, Dickinson GM. Genotypic analysis of plasma HIV-1 RNA soon after influenza vaccination of get LGK974 individuals with previously undetectable viral loads. AIDS. 2002; 16(four):537?2. 13. title= jp.2015.144 Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF, et al. Prevalence and predictive worth of intermittent viremia with mixture hiv therapy. JAMA. 2001;286(two):171?. 14. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitorbased extremely active antiretroviral therapy regimens are order NVS-SM1 equivalent in incidence and prognosis. Clin Infect Dis. 2005;41(9):1326?two. 15. Wojewoda CM, Spahlinger T, Harmon ML, Schnellinger B, Li Q, Dejelo C, Schmotzer C, Zhou L. Comparison of Roche Cobas AmpliPrep/Cobas title= j.toxlet.2015.11.022 TaqMan HIV-1 test version two.0 (CAP/CTM v2.0) with other real-time PCR assays in HIV-1 monitoring and follow-up of low-level viral loads.Bination antiretroviral therapy (cART). In: 14th European AIDS Conference (EACS 2013). Brussels; 2013. three. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, et al. ART suppresses plasma HIV-1 RNA to a steady set point predicted by pretherapy viremia. PLoS Pathog. 2007;3(4):e46. four. Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS. Young J, Rickenbach M, Calmy A, Bernasconi E, Staehelin C, Schmid P, Cavassini M, Battegay M, Gunthard HF, Bucher HC, et al. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infect Dis. 2015;15(1):382. 7. Stosor V, Palella Jr FJ, Berzins B, Till M, Leake A, Chmiel JS, Murphy RL. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis. title= s10803-012-1616-7 2005;41(11):1671?. 8. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr., Gallant JE, Quinn TC, Jackson B, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients getting HAART. JAMA. 2005; 293(7):817?9. 9. Jones LE, Perelson AS. Opportunistic infection as a cause of transient viremia in chronically infected HIV individuals below therapy with HAART. Bull Math Biol. 2005;67(six):1227?1. 10. Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Impact of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus getting potent antiretroviral therapy. J Infect Dis. 2000;181(two):522?1. 11. Jones LE, Perelson AS. Modeling the effects of vaccination on chronically infected HIV-positive sufferers. J Acquir Immune Defic Syndr. 2002;31(4):369?7. 12. Kolber MA, Gabr AH, De La Rosa A, Glock JA, Jayaweera D, Miller N, Dickinson GM. Genotypic evaluation of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS. 2002; 16(four):537?2. 13.